Beximco Pharmaceuticals Limited
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more
Beximco Pharmaceuticals Limited (BXP) - Net Assets
Latest net assets as of December 2024: GBX53.63 Billion GBX
Based on the latest financial reports, Beximco Pharmaceuticals Limited (BXP) has net assets worth GBX53.63 Billion GBX as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX73.80 Billion) and total liabilities (GBX20.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX53.63 Billion |
| % of Total Assets | 72.67% |
| Annual Growth Rate | 11.6% |
| 5-Year Change | 58.25% |
| 10-Year Change | 130.9% |
| Growth Volatility | 10.03 |
Beximco Pharmaceuticals Limited - Net Assets Trend (2005–2024)
This chart illustrates how Beximco Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beximco Pharmaceuticals Limited (2005–2024)
The table below shows the annual net assets of Beximco Pharmaceuticals Limited from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | GBX51.90 Billion | +8.99% |
| 2023-06-30 | GBX47.62 Billion | +6.68% |
| 2022-06-30 | GBX44.64 Billion | +19.46% |
| 2021-06-30 | GBX37.36 Billion | +13.93% |
| 2020-06-30 | GBX32.80 Billion | +9.82% |
| 2019-06-30 | GBX29.86 Billion | +9.19% |
| 2018-06-30 | GBX27.35 Billion | +9.09% |
| 2017-06-30 | GBX25.07 Billion | +8.73% |
| 2016-06-30 | GBX23.06 Billion | +2.58% |
| 2015-12-31 | GBX22.48 Billion | +7.45% |
| 2014-12-31 | GBX20.92 Billion | +5.79% |
| 2013-12-31 | GBX19.78 Billion | +7.43% |
| 2012-12-31 | GBX18.41 Billion | +7.47% |
| 2011-12-31 | GBX17.13 Billion | +7.22% |
| 2010-12-31 | GBX15.97 Billion | +46.74% |
| 2009-12-31 | GBX10.89 Billion | +4.17% |
| 2008-12-31 | GBX10.45 Billion | +26.65% |
| 2007-12-31 | GBX8.25 Billion | +3.78% |
| 2006-12-31 | GBX7.95 Billion | +16.56% |
| 2005-12-31 | GBX6.82 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beximco Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1202.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | GBX35.08 Billion | 73.16% |
| Common Stock | GBX4.46 Billion | 9.30% |
| Other Comprehensive Income | GBX1.45 Billion | 3.02% |
| Other Components | GBX6.96 Billion | 14.51% |
| Total Equity | GBX47.95 Billion | 100.00% |
Beximco Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Beximco Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eolus Vind AB
STU:7EVB
|
$31.62K |
|
HENGAN INTL GRP
MU:HGNC
|
$31.66K |
|
Lee Ku Industrial Co. Ltd.
KQ:025820
|
$31.68K |
|
Hansol Technics Co. Ltd.
KQ:004710
|
$31.69K |
|
Caspian Services Inc
PINK:CSSV
|
$31.59K |
|
JOPA3F
SA:JOPA3F
|
$31.59K |
|
SOGEFI
BE:GEF
|
$31.56K |
|
NIOX Group PLC
LSE:NIOX
|
$31.53K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beximco Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 43,680,704,000 to 47,949,964,744, a change of 4,269,260,744 (9.8%).
- Net income of 5,829,529,200 contributed positively to equity growth.
- Dividend payments of 1,585,900,722 reduced retained earnings.
- Other comprehensive income decreased equity by 3,872,066.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX5.83 Billion | +12.16% |
| Dividends Paid | GBX1.59 Billion | -3.31% |
| Other Comprehensive Income | GBX-3.87 Million | -0.01% |
| Other Changes | GBX29.50 Million | +0.06% |
| Total Change | GBX- | 9.77% |
Book Value vs Market Value Analysis
This analysis compares Beximco Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.40x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.92x to 0.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | GBX22.15 | GBX42.50 | x |
| 2006-12-31 | GBX25.81 | GBX42.50 | x |
| 2007-12-31 | GBX24.35 | GBX42.50 | x |
| 2008-12-31 | GBX28.27 | GBX42.50 | x |
| 2009-12-31 | GBX24.94 | GBX42.50 | x |
| 2010-12-31 | GBX29.84 | GBX42.50 | x |
| 2011-12-31 | GBX38.39 | GBX42.50 | x |
| 2012-12-31 | GBX41.26 | GBX42.50 | x |
| 2013-12-31 | GBX44.33 | GBX42.50 | x |
| 2014-12-31 | GBX46.89 | GBX42.50 | x |
| 2015-12-31 | GBX50.39 | GBX42.50 | x |
| 2017-06-30 | GBX56.20 | GBX42.50 | x |
| 2018-06-30 | GBX60.71 | GBX42.50 | x |
| 2019-06-30 | GBX66.32 | GBX42.50 | x |
| 2020-06-30 | GBX72.87 | GBX42.50 | x |
| 2021-06-30 | GBX83.01 | GBX42.50 | x |
| 2022-06-30 | GBX91.01 | GBX42.50 | x |
| 2023-06-30 | GBX97.91 | GBX42.50 | x |
| 2024-06-30 | GBX107.48 | GBX42.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beximco Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.16%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.13%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.45x
- Recent ROE (12.16%) is above the historical average (8.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 7.17% | 14.70% | 0.30x | 1.60x | GBX-192.86 Million |
| 2006 | 5.92% | 12.71% | 0.31x | 1.50x | GBX-324.32 Million |
| 2007 | 4.28% | 9.81% | 0.30x | 1.45x | GBX-472.09 Million |
| 2008 | 5.22% | 13.60% | 0.27x | 1.42x | GBX-499.66 Million |
| 2009 | 5.74% | 12.83% | 0.24x | 1.83x | GBX-463.80 Million |
| 2010 | 6.58% | 16.20% | 0.30x | 1.34x | GBX-545.67 Million |
| 2011 | 7.00% | 15.19% | 0.34x | 1.34x | GBX-514.38 Million |
| 2012 | 7.17% | 14.20% | 0.38x | 1.34x | GBX-521.43 Million |
| 2013 | 7.10% | 13.39% | 0.38x | 1.39x | GBX-572.79 Million |
| 2014 | 7.31% | 13.64% | 0.39x | 1.39x | GBX-563.72 Million |
| 2015 | 8.69% | 15.07% | 0.42x | 1.37x | GBX-293.58 Million |
| 2016 | 8.52% | 14.71% | 0.43x | 1.35x | GBX-340.57 Million |
| 2017 | 8.88% | 14.36% | 0.46x | 1.36x | GBX-280.55 Million |
| 2018 | 9.37% | 14.32% | 0.41x | 1.62x | GBX-171.65 Million |
| 2019 | 10.25% | 13.29% | 0.46x | 1.66x | GBX74.57 Million |
| 2020 | 10.82% | 13.72% | 0.51x | 1.54x | GBX265.18 Million |
| 2021 | 13.85% | 17.39% | 0.56x | 1.41x | GBX1.42 Billion |
| 2022 | 12.62% | 14.78% | 0.52x | 1.63x | GBX1.06 Billion |
| 2023 | 10.56% | 11.75% | 0.57x | 1.58x | GBX246.00 Million |
| 2024 | 12.16% | 13.13% | 0.64x | 1.45x | GBX1.03 Billion |
Industry Comparison
This section compares Beximco Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $41,953,936
- Average return on equity (ROE) among peers: 3.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beximco Pharmaceuticals Limited (BXP) | GBX53.63 Billion | 7.17% | 0.38x | $31.61K |
| Animalcare Group Plc (ANCR) | $78.80 Million | -0.10% | 0.40x | $23.67K |
| Alliance Pharma plc (APH) | $16.63 Million | 24.70% | 2.42x | $42.55K |
| Celadon Pharmaceuticals PLC (CEL) | $6.41 Million | -74.61% | 0.03x | $1.12K |
| Eco Animal Health Group Plc (EAH) | $9.77 Million | 20.11% | 0.69x | $8.46K |
| Hellenic Dynamics PLC (HELD) | $-102.20K | 0.00% | 0.00x | $1.05 |
| Indivior PLC (INDV) | $209.00 Million | 64.11% | 6.90x | $187.94K |
| N4 Pharma PLC (N4P) | $7.54 Million | 9.68% | 0.74x | $632.90 |
| Provexis plc (PXS) | $7.58 Million | -15.68% | 0.05x | $3.45K |